Crispr Therapeutics AG vs Quantumscape Corp — how do they compare? Crispr Therapeutics AG trades at $53.88 (market cap $5.23B), while Quantumscape Corp trades at $6.39 (market cap $3.90B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals.
| CRSP | QS | |
|---|---|---|
Market Cap | $5.23B | $3.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $18.44 |
52-Week Low | $44.34 | $4.89 |
Enterprise Value | $3.65B | $3.11B |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →